Blood Type Linked to Severity of Diarrhea
|
By LabMedica International staff writers Posted on 29 May 2018 |

Image: A computer-generated image of E. coli (Photo courtesy of Alissa Eckert and Jennifer Oosthuizen / CDC).
Enterotoxigenic Escherichia coli are responsible for millions of cases of diarrhea and hundreds of thousands of deaths every year, mainly of young children. It primarily infects people living in or visiting developing countries.
Some people infected with the bacterium develop severe, cholera-like, watery diarrhea that can be lethal. Others experience unpleasant symptoms but recover easily, while some do not get sick at all. A new study shows that a kind of E. coli most associated with "travelers' diarrhea" and children in underdeveloped areas of the world causes more severe disease in people with blood type A.
A team of scientists led by those at Washington University School of Medicine (St. Louis, MO, USA) carried out controlled human infection clinical trials, and gave healthy volunteers a dose of an E. coli strain originally isolated from a person in Bangladesh with severe, cholera-like diarrhea. Then, they observed the volunteers for five days. Those who developed moderate to severe diarrhea were treated with antibiotics. The disease comes on quickly, so anyone who was still healthy at the end of five days was unlikely to get sick later. Nonetheless, any remaining healthy participants also were given antibiotics to clear the bacteria before going home.
The investigators obtained data and blood samples from 106 people, each of whom participated in one of four such studies. They found that people with blood type A got sick sooner and more seriously than those of other blood types. More than eight out of 10 (81%) of blood group A people developed diarrhea that required treatment, as compared with about half of people with blood group B or O. They found that the bacteria produce a specific protein that sticks to A-type sugars, but not B- or O-type sugars, on intestinal cells. Since the protein also sticks to E. coli, it effectively fastens the bacteria to the intestinal wall, making it easy for them to deliver diarrhea-causing toxins to intestinal cells.
F. Matthew Kuhlmann, MD, a clinical investigator and a senior author of the study, said, “I don't want anyone to cancel their travel plans to Mexico because they have type A blood, Or the converse: I don't want anyone to think they're safe because their blood group is not A. There are a lot of different species of bacteria and viruses that can cause diarrhea, so even though this blood-group association is strong, it doesn't change your overall risk. You should continue taking the same precautions whatever your blood type.” The study was published on May 17, 2018, in The Journal of Clinical Investigation.
Related Links:
Washington University School of Medicine
Some people infected with the bacterium develop severe, cholera-like, watery diarrhea that can be lethal. Others experience unpleasant symptoms but recover easily, while some do not get sick at all. A new study shows that a kind of E. coli most associated with "travelers' diarrhea" and children in underdeveloped areas of the world causes more severe disease in people with blood type A.
A team of scientists led by those at Washington University School of Medicine (St. Louis, MO, USA) carried out controlled human infection clinical trials, and gave healthy volunteers a dose of an E. coli strain originally isolated from a person in Bangladesh with severe, cholera-like diarrhea. Then, they observed the volunteers for five days. Those who developed moderate to severe diarrhea were treated with antibiotics. The disease comes on quickly, so anyone who was still healthy at the end of five days was unlikely to get sick later. Nonetheless, any remaining healthy participants also were given antibiotics to clear the bacteria before going home.
The investigators obtained data and blood samples from 106 people, each of whom participated in one of four such studies. They found that people with blood type A got sick sooner and more seriously than those of other blood types. More than eight out of 10 (81%) of blood group A people developed diarrhea that required treatment, as compared with about half of people with blood group B or O. They found that the bacteria produce a specific protein that sticks to A-type sugars, but not B- or O-type sugars, on intestinal cells. Since the protein also sticks to E. coli, it effectively fastens the bacteria to the intestinal wall, making it easy for them to deliver diarrhea-causing toxins to intestinal cells.
F. Matthew Kuhlmann, MD, a clinical investigator and a senior author of the study, said, “I don't want anyone to cancel their travel plans to Mexico because they have type A blood, Or the converse: I don't want anyone to think they're safe because their blood group is not A. There are a lot of different species of bacteria and viruses that can cause diarrhea, so even though this blood-group association is strong, it doesn't change your overall risk. You should continue taking the same precautions whatever your blood type.” The study was published on May 17, 2018, in The Journal of Clinical Investigation.
Related Links:
Washington University School of Medicine
Latest Hematology News
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read moreMolecular Diagnostics
view channel
Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with heterogeneous biology that complicates prognostication and treatment selection. Genetic testing clarifies many drivers, yet it... Read more
Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more
Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
Lung cancer remains a leading cause of cancer death, and early-stage disease often produces few symptoms, complicating timely diagnosis and risk stratification. Conventional imaging and tissue biopsy have... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








